Biotech Investing During Bear Markets

Nov. 10, 2023

This article was originally published on Cowen.com

On this episode of the Biotech Decoded Podcast Series, Chris Garabedian, Co-Founder, Chairman, and CEO of Xontogeny and Portfolio Manager of the Perceptive Advisors Ventures Fund joins Yaron Werber, Biotechnology Analyst. Chris shares his insights about 1) what makes or breaks a successful biotech from his time at Gilead, Celgene, and Sarepta 2) how investing has changed now that interest rates are high and capital is expensive 3) his investment philosophy at Xontogeny and advice to other early-stage investors. Press play to listen to the podcast.

Subscribe to Spotify
Subscribe to Apple Podcasts

Portrait of Yaron Werber, M.D., MBA


Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

Portrait of Yaron Werber, M.D., MBA


Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

Portrait of Yaron Werber, M.D., MBA


Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

back to top